<div id="readability-page-1"><p>Rathbones Group PLC boosted its stake in  Novo Nordisk A/S (NYSE:NVO - Free Report) by 79.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,138 shares of the company's stock after acquiring an additional 32,270 shares during the period. Rathbones Group PLC's holdings in Novo Nordisk A/S were worth $3,721,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Novo Nordisk A/S</strong> alerts:</span></p></div><ul><li>Nuclear, Pharma &amp; Travel Buybacks: Confident or Cautious Signals?</li></ul><p>Other institutional investors have also added to or reduced their stakes in the company. True Wealth Design LLC boosted its holdings in  Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company's stock valued at $25,000 after acquiring an additional 300 shares during the last quarter.  Guerra Advisors Inc bought a new stake in  Novo Nordisk A/S in the third quarter valued at approximately $25,000.  Strengthening Families &amp; Communities LLC bought a new stake in  Novo Nordisk A/S in the third quarter valued at approximately $30,000.  American National Bank &amp; Trust bought a new stake in  Novo Nordisk A/S in the fourth quarter valued at approximately $28,000.  Finally, Allianz SE boosted its holdings in shares of  Novo Nordisk A/S by 70.0% during the 3rd quarter. Allianz SE now owns 578 shares of the company's stock worth $32,000 after buying an additional 238 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors. </p><h2>Novo Nordisk A/S Price Performance</h2><p>Shares of NYSE:NVO opened at $36.91 on Wednesday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The stock's 50 day moving average is $42.36 and its 200-day moving average is $49.38. The firm has a market capitalization of $164.78 billion, a price-to-earnings ratio of 10.64, a PEG ratio of 8.75 and a beta of 0.73. </p><ul><li>Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand</li></ul><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion.  Sell-side analysts forecast that  Novo Nordisk A/S will post 3.84 EPS for the current fiscal year. </p><h2>Novo Nordisk A/S Dividend Announcement</h2><p>The company also recently announced a  dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a dividend yield of 723.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S's dividend payout ratio  is presently 50.43%. </p><h2>Novo Nordisk A/S News Roundup</h2><ul><li>MarketBeat Week in Review – 03/09 - 03/13</li></ul><p>Here are the key news stories impacting Novo Nordisk A/S this week:</p><ul>   <li><span>Positive Sentiment: </span>Launched higher‑dose Wegovy (Wegovy HD 7.2 mg) nationwide in the U.S.; company says this dose delivers the largest weight-loss effect in the Wegovy franchise and is now broadly available, which should support prescription growth and higher average revenue per patient. <i></i><span>Novo Nordisk launches higher-dose Wegovy in U.S.</span></li>    <li><span>Positive Sentiment: </span>Oral Wegovy pill rollout is expanding the obesity market by bringing in new patients (not just converting injectables), which can enlarge total addressable market and diversify revenue streams versus injectable GLP‑1s. Media coverage highlights early strong demand. <i></i><span>Wegovy pill launch draws new patients</span></li>    <li><span>Positive Sentiment: </span>Company reaffirmed shareholder-friendly capital allocation with an ongoing share repurchase programme (part of up to DKK 15 billion over 12 months), a tangible near-term support for EPS and buy-side demand. <i></i><span>Share repurchase programme</span></li>    <li><span>Positive Sentiment: </span>CEO commentary that the weight‑loss drug boom has “barely begun” reinforces management's view of sustained demand and long runway for GLP‑1/obesity products, supporting bullish revenue forecasts. <i></i><span>CEO: weight-loss boom has barely begun</span></li>    <li><span>Neutral Sentiment: </span>Partnerships/market ripple effects: other companies (e.g., Hims &amp; Hers) are positioning to capture demand created by Novo’s products, which can expand distribution channels but are indirect to Novo’s near-term earnings. <i></i><span>Hims &amp; Hers taps into weight loss market</span></li>    <li><span>Negative Sentiment: </span>Analyst skepticism and downgrades citing GLP‑1 pipeline risks and competitive pressures (oral entrants from rivals like Lilly) highlight longer‑term execution and R&amp;D risk that could pressure multiple expansion. <i></i><span>Downgrade: GLP‑1 pipeline risks</span></li> </ul><h2>Analysts Set New Price Targets</h2><p>A number of equities analysts have issued reports on NVO shares. Sanford C. Bernstein started coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an &#34;outperform&#34; rating and a $175.00 price target on the stock. Weiss Ratings cut Novo Nordisk A/S from a &#34;hold (c-)&#34; rating to a &#34;sell (d+)&#34; rating in a report on Wednesday, March 18th. Jefferies Financial Group upgraded Novo Nordisk A/S from an &#34;underperform&#34; rating to a &#34;hold&#34; rating in a report on Thursday, February 12th. Nordea Equity Research cut Novo Nordisk A/S to a &#34;hold&#34; rating in a report on Tuesday, February 24th. Finally, Kepler Capital Markets cut Novo Nordisk A/S from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, nineteen have issued  a Hold rating and one  has issued  a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of &#34;Hold&#34; and an average price target of $65.56.</p><p><b>Check Out Our Latest Stock Report on NVO</b></p><h2>Novo Nordisk A/S Company Profile</h2> (Free Report)<p>Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support. </p><p>The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Novo Nordisk A/S</li></ul><p><strong>Want to see what other hedge funds are holding NVO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Rathbones Group PLC increased its stake in Novo Nordisk A/S by 79.0% in Q4, acquiring an additional 32,270 shares, bringing its total to 73,138 shares valued at $3.72 million. Other institutional investors also adjusted their holdings. Novo Nordisk's stock opened at $36.91, with a market cap of $164.78 billion. The company reported earnings of $1.01 per share, exceeding estimates, and announced a dividend of $1.2751 per share, yielding 723.0%. Positive sentiment surrounds the launch of higher-dose Wegovy and ongoing share repurchase programs.</p>

Rathbones Group PLC Buys 32,270 Shares of Novo Nordisk A/S $NVO